详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, PR China [2]Department of Genetics and Evolution, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia [3]Foshan hospital of TCM, Guangzhou University of Chinese Medicine, Foshan, Guangdong Province, PR China [4]Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, PR China [5]Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, PR China [6]Zhendong Pharmaceutical Research Institute Co., Ltd., Beijing, PR China [7]Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, PR China

出处：

DOI：

ISSN：

关键词： Non-small cell lung cancer Molecular mechanisms Gene regulation Drug sensitizing agent

摘要：

Gefitinib is one of commonly used first-line treatment options for patients with positive EGFR mutation in non-small cell lung cancer (NSCLC). However, most patients with gefitinib treatment relapse over time due to the loss of drug sensitivity. Compound Kushen injection (CKI) has been used to treat lung cancer, including EGFR-mutated NSCLC. In this report, we examined the anti-cancer and drug sensitivity increased activities of CKI in gefitinib less sensitive NSCLC cell lines H1650 and H1975. Bioinformatics analysis was applied to uncover gene regulation and molecular mechanisms of CKI. Our results indicated that when associating with gefitinib in a dose-dependent fashion, CKI demonstrated the ability to inhibit the proliferation and to increase the sensitivity to gefitinib treatment in gefitinib less sensitive cell lines. This could be the results of down regulation of the PI3K/Akt/mTOR pathway and up regulation of autophagy, which were identified as the potential primary targets of CKI to increase gefitinib treatment effect. Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 3 区医学：研究与实验 3 区药学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区药学

第一作者：

第一作者机构： [1]First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, PR China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Exosomal microRNA Therapy for Non-Small-Cell Lung Cancer [2]18β-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer [3]A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer. [4]Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI [5]Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy. [6]Targeting glycolysis in non-small cell lung cancer: Promises and challenges [7]Calponin 3 suppresses proliferation, migration and invasion of non-small cell lung cancer cells. [8]Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway [9]MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer [10]Tanshinone IIA Suppresses Non-Small Cell Lung Cancer Through Beclin-1-Mediated Autophagic Apoptosis

日	一	二	三	四	五	六

今天

清空